WHO ARE WE?
In 2019, Asia Orphan aimed to help people by creating global collaborations for the treatment of orphan diseases, because everyone has the right to health.
Our company, which has been operating since its establishment so that people with orphan diseases can access pharmaceutical medicines with appropriate treatments, is already a glimmer of hope for thousands of patients.
As AsiaOrphan, we work through international collaborations to enable access to the products needed by patients with rare and specialized treatment requirements. With our global supply network and regulation-compliant operational approach, we provide reliable and sustainable solutions that accelerate processes for healthcare professionals and institutions.
With our R&D and Innovation approach, we structure our product development processes within our R&D Center established in 2022; and as of 2023, we have been implementing active R&D projects that will strengthen our portfolio. In this way, we aim to contribute not only to today’s needs, but also to the treatment solutions of the future.
🔗 Explore Our R&D Activities
Our Company History
Asia Orphan was founded in 2005 with the aim of enabling access to medicines for patients with rare and specialized treatment needs.
Since its establishment, the company has focused on developing solutions to overcome access challenges, especially in the field of rare diseases…
